Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (mcsp)
AssigneeCelldex Therapeutics, Inc.
InventorsTibor Keler, Laura A. Vitale, Lizhen He
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided.
Claims28
A method of inducing cytolysis of a cell expressing human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP) (MCSP), comprising contacting the cell in the presence of an effector cell or complement, with an antibody that binds to the membrane-proximal domain of human MCSP, such that cytolysis of the cell occurs, wherein the membrane-proximal domain comprises the amino acid sequence set forth in SEQ ID NO:2.
(canceled)
An isolated antibody which binds to the membrane-proximal domain of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), wherein the membrane-proximal domain comprises the amino acid sequence set forth in SEQ ID NO:2 and wherein the antibody is capable of mediating cytolysis of a cell expressing MCSP in the presence of a human effector cell or complement.
(canceled)
A method of generating an immune response in a subject, comprising the steps of (a) vaccinating the subject with the membrane-proximal domain of human MCSP, or immunogenic portion thereof, and (b) generating antibodies against the domain, wherein the membrane-proximal domain comprises the amino acid sequence set forth in SEQ ID NO:2.
(canceled)
Dependencies are inferred from the claim text.